Literature DB >> 14742226

Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia.

Marc Leone1, Jacques Albanèse, Emmanuelle Sampol-Manos, Nicolas Simon, Bruno Lacarelle, Bernard Bruguerolle, Claude Martin.   

Abstract

The pharmacokinetics of moxifloxacin was studied in 17 mechanically ventilated patients with pneumonia. Patients were given 400 mg of moxifloxacin intravenously. Blood samples and bronchial secretions were taken on days 1 and 4. A dose of 400 mg of moxifloxacin allows one to achieve efficient concentrations in bronchial secretions and plasma.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14742226      PMCID： PMC321546          DOI： 10.1128/AAC.48.2.638-640.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy.

Authors:  A Soman; D Honeybourne; J Andrews; G Jevons; R Wise
Journal:  J Antimicrob Chemother       Date:  1999-12       Impact factor: 5.790

Review 2.  Role of newer fluoroquinolones in lower respiratory tract infections.

Authors:  H Lode; M Allewelt
Journal:  J Antimicrob Chemother       Date:  2002-05       Impact factor: 5.790

3.  A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus.

Authors:  P Gehanno; S Darantière; C Dubreuil; J C Chobaut; S Bobin; J C Pages; G Renou; F Bobin; P Arvis; H Stass
Journal:  J Antimicrob Chemother       Date:  2002-05       Impact factor: 5.790

4.  The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group.

Authors:  D K Heyland; D J Cook; L Griffith; S P Keenan; C Brun-Buisson
Journal:  Am J Respir Crit Care Med       Date:  1999-04       Impact factor: 21.405

5.  Effects of mechanical ventilation on release of cytokines into systemic circulation in patients with normal pulmonary function.

Authors:  H Wrigge; J Zinserling; F Stüber; T von Spiegel; R Hering; S Wetegrove; A Hoeft; C Putensen
Journal:  Anesthesiology       Date:  2000-12       Impact factor: 7.892

6.  Ofloxacin pharmacokinetics in mechanically ventilated patients.

Authors:  C Martin; D Lambert; B Bruguerolle; P Saux; J Freney; J Fleurette; H Meugnier; F Gouin
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

7.  Pharmacokinetics of antibiotics in critically ill patients.

Authors:  R van Dalen; T B Vree
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

8.  Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.

Authors:  R Finch; D Schürmann; O Collins; R Kubin; J McGivern; H Bobbaers; J L Izquierdo; P Nikolaides; F Ogundare; R Raz; P Zuck; G Hoeffken
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191
  8 in total
  2 in total

Review 1.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  Gender analysis of moxifloxacin clinical trials.

Authors:  Elisa Chilet-Rosell; Ma Teresa Ruiz-Cantero; Ma Angeles Pardo
Journal:  J Womens Health (Larchmt)       Date:  2013-11-01       Impact factor: 2.681
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.